Current News

Contact | Print version | PDF version | Send article | RSS feed

Oxford Genome Sciences and Medarex Sign Therapeutic Antibody Collaboration Agreement in Cancer

12 May 2006 - Oxford Genome Sciences (UK) Ltd and Medarex, Inc. announced that they have entered into a strategic collaboration to discover and develop new human antibody therapeutics for the treatment of cancers, including colorectal cancer.
 
The collaboration combines OGeS' ability to discover novel targets for oncology with Medarex's expertise in the development of fully human antibody therapeutics. The collaboration provides for OGeS and Medarex to discover, develop and commercialize therapeutic antibodies on a 50:50 basis. Other financial terms of the agreement were not disclosed.
 
During the initial phase of the collaboration, OGeS intends to provide novel colorectal cancer targets, against which Medarex expects to generate fully human monoclonal antibodies using its proprietary UltiMAb Human Antibody Development System(r). OGeS plans to utilize its unique Oxford Genome Anatomy Project (OGAP(r)) database.